Clinical study of remazolam combined with alfentanil moderate sedation during gastroscopy in patients with snoring

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032063

Enrollment

Unknown

Registered

2020-04-19

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

snoring

Interventions

experimental group:Slowly infuse 7-10 µg / kg of fentanyl, and then slowly intravenously inject remazolam 1.5-3 mg until the patient's BIS value is between 70-80

control group:Conventional propofol deep sedation 1.5-2.5mg / kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 160 patients with snoring who chose painless gastroscopy, aged 20-65 years, ASA grade I-II.

Exclusion criteria

Exclusion criteria: The following patients were not included in this study: patients with nocturnal wakefulness or severe snoring who had been diagnosed with obstructive sleep apnea syndrome (OSAS); have severe cardiovascular and cerebrovascular diseases, heart block disease, liver and kidney function insufficiency and neuropsychiatric disorders; pregnancy, breastfeeding, or recent pregnancy preparation; allergy to propofol or opioids; painless gastroscopy anesthesia or surgical contraindications, which the researchers believe may affect patient safety during the study.

Design outcomes

Primary

Measure	Time frame
Incidence of hypoxemia;Body movement rate;	—

Secondary

Measure	Time frame
Hemodynamics;	—

Countries

China

Contacts

Public ContactShuai Kang

Jiaxing Second Hospital

15024340122@163.com+86 15024340122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026